Shares of Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) were down 1.7% during trading on Friday . The stock traded as low as $31.96 and last traded at $32.00, with a volume of 111,681 shares trading hands. The stock had previously closed at $32.54.

Several analysts have commented on ALDR shares. Jefferies Group reiterated a “buy” rating and set a $61.00 target price on shares of Alder BioPharmaceuticals in a research report on Thursday, June 9th. Zacks Investment Research upgraded shares of Alder BioPharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, May 30th. Finally, Brean Capital reiterated a “positive” rating and set a $45.00 target price on shares of Alder BioPharmaceuticals in a research report on Wednesday, July 27th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Alder BioPharmaceuticals has a consensus rating of “Buy” and a consensus target price of $44.00.

The stock’s market capitalization is $1.58 billion. The company’s 50 day moving average price is $30.39 and its 200-day moving average price is $26.28.

Alder BioPharmaceuticals (NASDAQ:ALDR) last announced its quarterly earnings data on Tuesday, July 26th. The biopharmaceutical company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by $0.04. The company had revenue of $0.11 million for the quarter, compared to analyst estimates of $1.14 million. Alder BioPharmaceuticals’s revenue was up 112900.0% compared to the same quarter last year. During the same quarter last year, the business earned ($0.46) earnings per share. On average, equities analysts expect that Alder BioPharmaceuticals Inc. will post ($2.76) earnings per share for the current year.

In other Alder BioPharmaceuticals news, VP Jeffrey T. L. Smith sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $31.17, for a total value of $93,510.00. Following the sale, the vice president now owns 3,000 shares in the company, valued at $93,510. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Mark James Litton sold 6,000 shares of the firm’s stock in a transaction that occurred on Monday, June 13th. The shares were sold at an average price of $28.94, for a total transaction of $173,640.00. Following the completion of the sale, the insider now owns 74,567 shares in the company, valued at approximately $2,157,968.98. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Alder BioPharmaceuticals stock. Wells Fargo & Company MN increased its stake in shares of Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) by 290.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 269,774 shares of the biopharmaceutical company’s stock after buying an additional 200,707 shares during the period. Wells Fargo & Company MN owned about 0.62% of Alder BioPharmaceuticals worth $8,911,000 as of its most recent SEC filing.

Alder Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and focuses to commercialize therapeutic antibodies with the potential to transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy, as well as speed of onset and durability of therapeutic response.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.